257 results on '"Maina, Flavio"'
Search Results
2. SAT-183 Moderate overexpression of c-Met in hepatocytes decreases cholestatic liver injury
3. MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities
4. Uncovering a Novel Functional Interaction Between Adult Hepatic Progenitor Cells, Inflammation and EGFR Signaling During Bile Acids-Induced Injury.
5. Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography
6. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis
7. Mitogen-Inducible Gene 6 Is an Endogenous Inhibitor of HGF/Met-Induced Cell Migration and Neurite Growth
8. Data from Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors
9. Figure S4 from Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors
10. Table S2 from Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors
11. Supplementary Figures S1-S7 from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
12. Data from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
13. Supplementary Tables S1-S7 from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
14. Supplementary Methods and References from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
15. p53 Inhibitors as Cancer Sensitizing Agents
16. A phosphokinome‐based screen uncovers new drug synergies for cancer driven by liver‐specific gain of nononcogenic receptor tyrosine kinases
17. Publisher Correction: Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer
18. Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer
19. MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities
20. Enhanced wild-Type mET Receptor levels in mouse hepatocytes attenuates insulin-mediated signaling
21. Identification of new aminoacid amides containing the imidazo[2,1- b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling
22. Enhanced Wild-Type MET Receptor Levels in Mouse Hepatocytes Attenuates Insulin-Mediated Signaling
23. Genetic analysis of specific and redundant roles for p38α and p38β MAPKs during mouse development
24. Disruption of Epithelial Integrity Drives Mesendoderm Differentiation in Human Induced Pluripotent Stem Cells by Enabling BMP and ACTIVIN Sensing
25. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma
26. The AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC
27. BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators
28. Turning up our understanding of liver cancer by a notch
29. Enhanced differentiation of human induced pluripotent stem cells toward the midbrain dopaminergic neuron lineage through GLYPICAN-4 downregulation
30. C3G Is Upregulated in Hepatocarcinoma, Contributing to Tumor Growth and Progression and to HGF/MET Pathway Activation
31. Two is better than one: combinatorial receptor targeting enhances hepatocellular carcinoma (HCC) therapeutic response
32. Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
33. Hepatocyte growth factor protects retinal ganglion cells by increasing neuronal survival and axonal regeneration in vitro and in vivo
34. Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis
35. C3G Is Upregulated in Hepatocarcinoma, Contributing to Tumor Growth and Progression and to HGF/MET Pathway Activation
36. Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type
37. Somitic origin of the medial border of the mammalian scapula and its homology to the avian scapula blade
38. Analysis of c-Met Kinase Domain Complexes: A New Specific Catalytic Site Receptor Model for Defining Binding Modes of ATP-Competitive Ligands
39. BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators.
40. Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt–dependent manner
41. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development
42. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family
43. Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9
44. Tracking Dynamics of Spontaneous Tumours in Mice Using Photon Counting Computed Tomography
45. Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance.
46. Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors
47. Genomic MET amplification occurs early in NF1-related malignant peripheral nerve sheath tumor (MPNST) progression and is a potent therapeutic target
48. Oncogenic RAS-MET signal interactions are modulated by P53 status in NF1-related MPNSTs
49. Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells
50. ‘Click’ synthesis of a triazole-based inhibitor of Met functions in cancer cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.